Daclizumab: another option for highly active relapsing ‐remitting MS

Daclizumab provides clinicians with a new treatment option for patients with relapsing‐remitting multiple sclerosis. Here the authors consider its benefits compared with other multiple sclerosis drugs and its likely place in therapy.
Source: Progress in Neurology and Psychiatry - Category: Neurology Authors: Tags: Comment Source Type: research